A retrospective observational study of glucocorticoid-induced diabetes mellitus with IgA nephropathy treated with tonsillectomy plus methylprednisolone pulse therapy

Yoshia Miyawaki, Takayuki Katsuyama, Kenei Sada, Sumie Hiramatsu, Keiji Ohashi, Michiko Morishita, Eri Katsuyama, Haruki Watanabe, Mariko Takano-Narazaki, Noriko Toyota-Tatebe, Katsue Sunahori-Watanabe, Tomoko Kawabata, Tatsuyuki Inoue, Masaru Kinomura, Hitoshi Sugiyama, Jun Wada

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aims To evaluate the incidence of GC-DM among patients with immunoglobulin A nephropathy (IgAN) and to confirm the risk factors for the development of GC-DM. Methods The medical records of patients with IgAN newly treated with the protocol of tonsillectomy combined with steroid pulse therapy were reviewed. The primary outcome was the development of GC-DM within the hospitalization period and during one year of follow-up. Results During hospitalization, 19 of the 95 patients developed GC-DM (20.0%), and the patients with GC-DM were significantly older and had a higher rate of family history of diabetes and higher HbA1c levels. The prevalence of hypertension was higher and the EGFR was numerically lower in patients with GC-DM than in those without. Older age (≥45 years) and a family history of diabetes emerged as independent risk factors for the development of GC-DM (odds ratio [OR], 6.3 and 95% confidence interval [CI], 1.6-27.6; OR, 4.4 and 95% CI, 1.2- 16.6, respectively). No patients were newly diagnosed with GC-DM during 1-year observation period at out-patient clinic. Conclusions Among the patients with IgAN, 20% developed GC-DM during the hospitalization period, confirming the family history of diabetes is clinically necessary before starting GC therapy.

Original languageEnglish
Article numbere0178018
JournalPLoS One
Volume12
Issue number5
DOIs
Publication statusPublished - May 1 2017

Fingerprint

Tonsillectomy
Methylprednisolone
observational studies
Medical problems
diabetes mellitus
glucocorticoids
kidney diseases
Immunoglobulin A
Glucocorticoids
Observational Studies
Diabetes Mellitus
Retrospective Studies
IGA Glomerulonephritis
therapeutics
immunoglobulin A
Hospitalization
diabetes
Therapeutics
Steroids
odds ratio

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

A retrospective observational study of glucocorticoid-induced diabetes mellitus with IgA nephropathy treated with tonsillectomy plus methylprednisolone pulse therapy. / Miyawaki, Yoshia; Katsuyama, Takayuki; Sada, Kenei; Hiramatsu, Sumie; Ohashi, Keiji; Morishita, Michiko; Katsuyama, Eri; Watanabe, Haruki; Takano-Narazaki, Mariko; Toyota-Tatebe, Noriko; Sunahori-Watanabe, Katsue; Kawabata, Tomoko; Inoue, Tatsuyuki; Kinomura, Masaru; Sugiyama, Hitoshi; Wada, Jun.

In: PLoS One, Vol. 12, No. 5, e0178018, 01.05.2017.

Research output: Contribution to journalArticle

Miyawaki, Yoshia ; Katsuyama, Takayuki ; Sada, Kenei ; Hiramatsu, Sumie ; Ohashi, Keiji ; Morishita, Michiko ; Katsuyama, Eri ; Watanabe, Haruki ; Takano-Narazaki, Mariko ; Toyota-Tatebe, Noriko ; Sunahori-Watanabe, Katsue ; Kawabata, Tomoko ; Inoue, Tatsuyuki ; Kinomura, Masaru ; Sugiyama, Hitoshi ; Wada, Jun. / A retrospective observational study of glucocorticoid-induced diabetes mellitus with IgA nephropathy treated with tonsillectomy plus methylprednisolone pulse therapy. In: PLoS One. 2017 ; Vol. 12, No. 5.
@article{c93c1ce209204c3d8c43b3b8a366f1d1,
title = "A retrospective observational study of glucocorticoid-induced diabetes mellitus with IgA nephropathy treated with tonsillectomy plus methylprednisolone pulse therapy",
abstract = "Aims To evaluate the incidence of GC-DM among patients with immunoglobulin A nephropathy (IgAN) and to confirm the risk factors for the development of GC-DM. Methods The medical records of patients with IgAN newly treated with the protocol of tonsillectomy combined with steroid pulse therapy were reviewed. The primary outcome was the development of GC-DM within the hospitalization period and during one year of follow-up. Results During hospitalization, 19 of the 95 patients developed GC-DM (20.0{\%}), and the patients with GC-DM were significantly older and had a higher rate of family history of diabetes and higher HbA1c levels. The prevalence of hypertension was higher and the EGFR was numerically lower in patients with GC-DM than in those without. Older age (≥45 years) and a family history of diabetes emerged as independent risk factors for the development of GC-DM (odds ratio [OR], 6.3 and 95{\%} confidence interval [CI], 1.6-27.6; OR, 4.4 and 95{\%} CI, 1.2- 16.6, respectively). No patients were newly diagnosed with GC-DM during 1-year observation period at out-patient clinic. Conclusions Among the patients with IgAN, 20{\%} developed GC-DM during the hospitalization period, confirming the family history of diabetes is clinically necessary before starting GC therapy.",
author = "Yoshia Miyawaki and Takayuki Katsuyama and Kenei Sada and Sumie Hiramatsu and Keiji Ohashi and Michiko Morishita and Eri Katsuyama and Haruki Watanabe and Mariko Takano-Narazaki and Noriko Toyota-Tatebe and Katsue Sunahori-Watanabe and Tomoko Kawabata and Tatsuyuki Inoue and Masaru Kinomura and Hitoshi Sugiyama and Jun Wada",
year = "2017",
month = "5",
day = "1",
doi = "10.1371/journal.pone.0178018",
language = "English",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - A retrospective observational study of glucocorticoid-induced diabetes mellitus with IgA nephropathy treated with tonsillectomy plus methylprednisolone pulse therapy

AU - Miyawaki, Yoshia

AU - Katsuyama, Takayuki

AU - Sada, Kenei

AU - Hiramatsu, Sumie

AU - Ohashi, Keiji

AU - Morishita, Michiko

AU - Katsuyama, Eri

AU - Watanabe, Haruki

AU - Takano-Narazaki, Mariko

AU - Toyota-Tatebe, Noriko

AU - Sunahori-Watanabe, Katsue

AU - Kawabata, Tomoko

AU - Inoue, Tatsuyuki

AU - Kinomura, Masaru

AU - Sugiyama, Hitoshi

AU - Wada, Jun

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Aims To evaluate the incidence of GC-DM among patients with immunoglobulin A nephropathy (IgAN) and to confirm the risk factors for the development of GC-DM. Methods The medical records of patients with IgAN newly treated with the protocol of tonsillectomy combined with steroid pulse therapy were reviewed. The primary outcome was the development of GC-DM within the hospitalization period and during one year of follow-up. Results During hospitalization, 19 of the 95 patients developed GC-DM (20.0%), and the patients with GC-DM were significantly older and had a higher rate of family history of diabetes and higher HbA1c levels. The prevalence of hypertension was higher and the EGFR was numerically lower in patients with GC-DM than in those without. Older age (≥45 years) and a family history of diabetes emerged as independent risk factors for the development of GC-DM (odds ratio [OR], 6.3 and 95% confidence interval [CI], 1.6-27.6; OR, 4.4 and 95% CI, 1.2- 16.6, respectively). No patients were newly diagnosed with GC-DM during 1-year observation period at out-patient clinic. Conclusions Among the patients with IgAN, 20% developed GC-DM during the hospitalization period, confirming the family history of diabetes is clinically necessary before starting GC therapy.

AB - Aims To evaluate the incidence of GC-DM among patients with immunoglobulin A nephropathy (IgAN) and to confirm the risk factors for the development of GC-DM. Methods The medical records of patients with IgAN newly treated with the protocol of tonsillectomy combined with steroid pulse therapy were reviewed. The primary outcome was the development of GC-DM within the hospitalization period and during one year of follow-up. Results During hospitalization, 19 of the 95 patients developed GC-DM (20.0%), and the patients with GC-DM were significantly older and had a higher rate of family history of diabetes and higher HbA1c levels. The prevalence of hypertension was higher and the EGFR was numerically lower in patients with GC-DM than in those without. Older age (≥45 years) and a family history of diabetes emerged as independent risk factors for the development of GC-DM (odds ratio [OR], 6.3 and 95% confidence interval [CI], 1.6-27.6; OR, 4.4 and 95% CI, 1.2- 16.6, respectively). No patients were newly diagnosed with GC-DM during 1-year observation period at out-patient clinic. Conclusions Among the patients with IgAN, 20% developed GC-DM during the hospitalization period, confirming the family history of diabetes is clinically necessary before starting GC therapy.

UR - http://www.scopus.com/inward/record.url?scp=85020020626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020020626&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0178018

DO - 10.1371/journal.pone.0178018

M3 - Article

C2 - 28562629

AN - SCOPUS:85020020626

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e0178018

ER -